February 27th 2019
Social Survey Research Information Co., Ltd.
PatientsMap 2018 CHINA Data analysis part 2
Manufacturer cover ranking per department
Visitation rate of Sales Rep of Japanese companies to Chinese doctors
Santen stands out as a top company with 63% in ophthalmology
In other Japanese companies, Astellas ranked 4th with 33% in urology, Eisai ranked 5th with 29% in neurology
Looking at the top 5 rankings for the 10 departments from all 32 target departments, while global major companies such as AZ, Pfizer and Bayer are in the top position, some Chinese companies such as CTTQ also ranked high.
As for Japanese companies, Santen was first place with 62.8% in ophthalmology. And Astellas came in fourth in urology and Eisai in fifth in neurology. (fig 1)
After the 6th place, Otsuka was 7th place in psychiatry, Dainippon Sumitomo was 9th place, Daiichi Sankyo was 9th place in respiratory, Takeda was 11th place in urology, etc. The result shows that Japanese companies seem to be penetrating the Chinese market
In the future, we plan to provide analysis data on MR coverage for all 32 medical departments in China for companies in Europe, the United States and Europe.
Table 1. Top 5 companies ranking in 10 top medical departments for Sales Rep visit recognition based on Patients Map2018 CN
Rank | Internal Medicine Dept. n=1328 |
Respiratory Dept. n=414 |
Gastroenterology Dept. n=476 |
Cardiology Dept. n=1105 |
Diabetology/ Endocrinology Dept. n= 536 |
|||||
1 | Bayer | 29.7 | AZ | 55.8 | AZ | 48.7 | AZ | 55.5 | Novo | 64.6 |
2 | Pfizer | 26.8 | Pfizer | 47.3 | CTTQ | 30.0 | Pfizer | 54.0 | Bayer | 54.3 |
3 | AZ | 26.7 | GSK | 45.2 | Bayer | 25.8 | Bayer | 51.1 | Sanofi | 52.4 |
4 | Novo | 20.4 | Bayer | 41.3 | GSK | 25.4 | Sanofi | 41.6 | Eli Lilly | 48.7 |
5 | Sanofi | 20.0 | MSD | 35.3 | Janssen | 21.0 | Novartis | 34.4 | AZ | 38.2 |
Psychiatry Dept. n=436 |
Neurology Dept. n=1046 |
Hematology Dept. n=214 |
Ophthalmology Dept. n=172 |
Urology Dept. n=200 |
||||||
1 | Janssen | 59.0 | Pfizer | 51.0 | Pfizer | 58.4 | Santen | 62.8 | MSD | 44.0 |
2 | Eli Lilly | 41.5 | Bayer | 46.0 | Janssen | 57.5 | Novartis | 55.8 | AZ | 43.5 |
3 | JHP | 41.2 | Sanofi | 35.5 | CTTQ | 53.3 | Pfizer | 19.8 | Pfizer | 39.0 |
4 | Pfizer | 37.6 | AZ | 34.3 | MSD | 51.4 | Qilu | 16.9 | Astellas | 33.0 |
5 | Qilu | 25.5 | Eisai | 28.7 | Novartis | 47.7 | Eisai | 14.5 | Janssen | 28.5 |
<Reference: July 5, 2018 Press Release>
Table 2. PatientsMap2018 CN- Top 15 Sales Rep visit ranking(n=10,285)
Overall rank | Company name | N= | % |
1 | Pfizer | 3,626 | 35.3% |
2 | Astra Zeneca | 3,229 | 31.4% |
3 | Bayer | 3,123 | 30.4% |
4 | MSD | 2,381 | 23.2% |
5 | Sanofi | 2,134 | 20.7% |
6 | Novartis | 1,954 | 19.0% |
7 | GlaxoSmithKline | 1,736 | 16.9% |
8 | CHIA TAI TIANQING (CTTQ) Pharmaceutical | 1,675 | 16.3% |
9 | Roche | 1,651 | 16.1% |
10 | Yangtze River Pharmaceutical (Group) | 1,618 | 15.7% |
11 | Janssen | 1,598 | 15.5% |
12 | Qilu Pharmaceutical | 1,413 | 13.7% |
13 | Eli Lilyイ | 1,398 | 13.6% |
14 | Novo Nordisk | 1,244 | 12.1% |
15 | Jiangsu Hengrui Medicine Distribution | 1,176 | 11.4% |
Table 3. PatientsMap2018 CN- Top 15 Sales Rep visit ranking- Japanese companies(n=10,285)
Overall rank | Company name | n= | % |
21 | Eisai | 836 | 8.1% |
27 | Takeda | 488 | 4.7% |
30 | Daiichi Sankyo | 480 | 4.7% |
32 | Otsuka | 401 | 3.9% |
37 | Sumitomo Dainippon Pharma | 340 | 3.3% |
43 | Astellas | 232 | 2.3% |
47 | Santen | 162 | 1.6% |
_______________________________________
“PatientsMap 2018CN” – Outline-
The respondents of this study was randomly selected per specialty/department from members of medlive.cn, administrated by Chinese affliate of m3.com and is a portal site for healthcare professionals with 2,130,000 online members,.
Studied medical conditions: 357 conditions
Sample source: M3 Global Research online physician panel
Sample department: All departments in hospitals and clinics
Methodology: Online survey
Sample size: Total of 10,285 physicians
Fieldwork schedule: 3rd January 2018~6th March 2018
Contents of the survey: Medical conditions that they treat
Number of patients they see per medical condition
Number of patients in which they administer medicine to
Medical conditions in which they wish for new products
Sales rep visitation status
- This service is provided jointly by Social Survey Research Co., Ltd., M3, Inc. and M3 Global Research.
■Contact Information Social Survey Research Information Co., Ltd
Contact: Chiharu Sakai
℡:03-6709-9710
e-mail:patientsmap@ssri.com
- Social Survey Research Information Co., Ltd
Established April 1982
Capital 27 million yen
Executive President & CEO Takashi Makita
Staff 110 staff members
Address NMF Shinjuku EAST Bldg.
10-5 Tomihisacho, Shinjuku-ku, Tokyo 162-0067
JAPAN
Osaka Office Tetsutani Bldg. 502
2-2-2 Tokui-cho, Chuo-ku, Osaka540-0025
JAPAN
Affiliate companies PD Research Co., Ltd.
SSRI-CHINA Co., Ltd.
URL http://www.ssri.com/index.html
- M3, Inc.
Established September 2000
Capital 15 billion and 31 million yen
Director Representative Director Itaru Tanimura
Subsidiaries staff 3,556 staff members (as of end of March 2016)
Address Akasaka Intercity 10th floor
1-11-44 Akasaka
Minato-ku, Tokyo 107-0052
JAPAN
URL http://corporate.m3.com/
- Medlive.cn
Established: April 2013
Capital: 2 million CNY
General manager: Tian Liping
Number of staffs: 210
Address: Beijing Red Manor International Bonded Innovation Park E-1,
Baijialou 1, Chaoyang North Road, Chaoyang District,
Beijing 100024